Iridex Q1 revenue $11.8M (-1% YoY); net loss narrows to $0.5M; Cyclo G6 up 14%

IRIDEX CORP

2026-Q1 EPS reported -$0.03 vs consensus -$0.07 ▲ beat (+58.0%)

Revenue $11.8M, down 1% YoY; Cyclo G6 product revenue $3.6M (+14% YoY) on 15,500 probes sold.
Net loss $0.5M ($0.03/sh) compared to $1.7M ($0.10/sh) in Q1 2025; Non-GAAP adjusted EBITDA $0.3M.
Gross margin 40% vs 43% a year ago, pressured by tariffs and transition to low-cost manufacturers.
Cash $4.6M; company expects positive cash flow for full year 2026 despite typical Q1 usage.
FY2026 revenue guidance reaffirmed at $51M-$53M; adjusted opex guided $19M-$19.5M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRIDEX CORP reported first quarter ended April 4, 2026 results: revenue $11.8 million, net income $0.5 million or $0.03 per share, EPS $0.03 per share. Guidance reaffirmed.

Period: first quarter ended April 4, 2026
Revenue: $11.8 million
Net income: $0.5 million or $0.03 per share
EPS: $0.03 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

glaucoma and retinal diseases, today reported financial results for the first quarter ended April 4, 2026. First Quarter 2026 Financial Highlights • Generated total revenue of $11.8 million, compared to $11.9 million in the prior year period • Cyclo G6® product family revenue was $3.6 million, representing growth of 14% year-over-year compared to $3.2 million in the

View on SEC.gov

Browse all earnings releases →

IRIDEX CORP filing history →

Source: SEC EDGAR

accession 0001193125-26-230774

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.